From 04/01/2018 – 06/30/2018
Proposal Title, ID#, Sponsor, Dates, Direct Cost, Indirect Cost, Total Cost
Chatzizisis, Ioannis S, Study of Access site for Enhancing PCI in STEMI for Seniors, 21288, Duke Clinical Research Institute, 04/13/18-04/12/20, $0, $2,940, $2,940
Study of Access site for Enhancing PCI in STEMI for Seniors, 21288, Duke Clinical Research Institute, 04/13/18-04/12/20, $18,079, $981, $19,060
Duan, Bin, 3D Bioprinting of Biomimetic Constructs for Rotator Cuff Augmentation, 21244, DHHS/NIH/NIAMS, 06/01/18-05/31/19, $185,116, $97,186, $282,302
Gumina, Richard J, Nucleotidases in atherothrombosis, 22083, American Heart Association – National, 01/01/18-06/30/18, $53,248, $5,325, $58,573
RoboSep-5, 22021, NE. Bankers Assoc. Equipment Grants / U.N. Fdn, 04/05/18-04/04/19, $15,000, $0, $15,000
Nucleotidases in atherothrombosis, 22083, American Heart Association – National, 07/01/18-06/30/19, $70,000, $7,000, $77,000
Lowes, Brian D, PROVIDE-HF: Patient Reported Outcomes Investigation Following Initiation of Drug Therapy with Entresto (Sacubitril/Valsartan) in Heart Failure No. Y8W00090, 22188, University of Kansas Medical Center Research Institute Inc, 01/12/18-12/31/19, $16,379, $8,435, $24,814
Porter, Thomas Richard, Dodecafluoropentane Animal Expenses, 22061, NuvOx Pharma, LLC, 04/01/17-09/30/18, $120,840, $0, $120,840
Windle, John Robert, PEW Healthcare Data Interoperability Project, 22144, Duke Clinical Research Institute, 04/01/18-09/30/18, $7,405, $649, $8,054
Desouza, Cyrus Victor, Effect and safety of semaglutide 2.4 mg once- weekly in subjects with overweight or obesity who have reached target dose during run-in period, 21958, Novo Nordisk Pharmaceuticals, Inc., 05/25/18-05/24/20, $0 , $29,029, $29,029
Effect and safety of semaglutide 2.4 mg once- weekly in subjects with overweight or obesity who have reached target dose during run-in period, 21958, Novo Nordisk Pharmaceuticals, Inc., 05/25/18-05/24/20, $149,868 , $9,677, $159,545
Kharbanda, Kusum K, Impaired phospholipid methylation results in decreased lipid droplets lipolysis: role in hepatic steatosis, 21177, DHHS/NIH/NIAAA, 05/05/18-03/31/19, $249,661, $64,912, $314,573
Ouellette, Michel M, RAC1 GTPase in tumorigenesis and progression of pancreatic cancer, 19286, DHHS/NIH/NCI, 05/01/18-04/30/19, $249,000, $125,745, $374,745
Rasineni, Karuna, Pancreas-Adipose-Liver Axis: Role of Ghrelin and Insulin in Alcoholic Fatty Liver, 19221, DHHS/NIH/NIAAA, 05/01/18-04/30/19, $111,705, $8,936, $120,641
Rochling, Fedja A, A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study, to evaluate the effects of two doses of MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC) and an inadequate response to ursodeoxycholic acid (UDCA), 19360, CymaBay Therapeutics, Inc., 03/10/16-03/09/17, $0 , ($12,582), ($12,582)
A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study, to evaluate the effects of two doses of MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC) and an inadequate response to ursodeoxycholic acid (UDCA), 19360, CymaBay Therapeutics, Inc., 03/10/16-03/09/17, ($64,679), ($4,043), ($68,722)
Kalil, Andre C, A Phase 2 Proof-of-Concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa & A Phase 2 Randomized, Double-Blind, Placebo, Dose-Ranging…, 21527, Rhode Island Hospital, 03/01/18-04/30/19, $7,409, $1,926, $9,335
Rupp, Mark E, An Open-label, Prospective, Observational Study of the Wear Time of an Investigational Antimicrobial Dressing containing CHG, 20174, 3M Company, 11/09/16-02/08/18, $0 , $1,081 , $1,081
An Open-label, Prospective, Observational Study of the Wear Time of an Investigational Antimicrobial Dressing containing CHG, 20174, 3M Company, 11/09/16-02/08/18, $5,360 , $544 , $5,903
NEBRASKA ANTIMICROBIAL STEWARDSHIP ASSESSMENT AND PROMOTION (NEBRASKA ASAP) SUBAWARD, 21053, NE DHHS, 08/01/17-07/31/18, $10,500, $0, $10,500
Develop a Fully Autoclavable Respirator for the Biomedical Advanced Research and Development Authority (BARDA), 20994, Applied Research Associates, Inc., 12/31/17-12/31/18, $25,197, $588, $25,785
Swindells, Susan, AIDS Drug Assistance Program [ADAP] Ryan White Title II Program (Part B), 21175, NE DHHS, 04/01/17-03/31/18, $1,429,627, $0, $1,429,627
Title III:Categorical Grant Program to Provide Outpatient Early Intervention Services with Respect to HIV Disease (Ryan White Part C Outpatient EIS Program), 6247, DHHS/HRSA, 01/01/18-12/31/18, $182,920 , $0 , $182,920
Vanschooneveld, Trevor Craig, A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)., 17826, Actelion Pharmaceuticals US, Inc., 08/04/14-08/03/16, $0 , ($18,570), ($18,570) A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)., 17826, Actelion Pharmaceuticals US, Inc., 08/04/14-08/03/16, ($91,705), ($5,798), ($97,503)
Ernani, Vinicius, Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC), 21460, Big Ten Cancer Research Consortium, 03/29/18-03/28/19, $37,417, $9,468 , $46,885
Lunning, Matthew A, A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects with Various Lymphomas and Leukemias, 21398, miRagen, 04/14/18-04/13/20, $0 , $20,315 , $20,315
A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects with Various Lymphomas and Leukemias, 21398, miRagen, 04/14/18-04/13/20, $107,177, $6,771, $113,948
Long-term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells, 21365, Celgene Corporation, 05/04/18-12/31/25, $0, $17,266, $17,266
Long-term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells, 21365, Celgene Corporation, 05/04/18-12/31/25, $91,544, $5,755, $97,299
Bailey, Kristina Lynn, Mucociliary clearance in aging, 19544, DHHS/NIH/NIA, 06/15/18-04/30/19, $205,000, $103,525, $308,525
Grant, Kathleen M, Probation and parole process evaluation, 22067, Nebraska Administrative Office of Probation, 04/01/18-09/30/19, $50,465, $5,046, $55,511
Murphy, P. James James, A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of PTI-808 in Healthy Subjects and in Adults with Cystic Fibrosis, 21870, Proteostasis Therapeutics, Inc., 05/14/18-05/13/20, $0, $10,870, $10,870
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of PTI-808 in Healthy Subjects and in Adults with Cystic Fibrosis, 21870, Proteostasis Therapeutics, Inc., 05/14/18-05/13/20, $60,742, $3,623, $64,365
Rennard, Stephen Israel, Defining the Role of Early Pulmonary Vascular Disease in COPD, 19225, University of Iowa, 04/01/18-03/31/19, $6,842, $3,523, $10,365
Thompson, Austin Bassett, Multicenter, retrospective chart review of first-time Opsumit (macitentan) users in the United States, 21447, Actelion Pharmaceuticals Ltd., 04/27/18-04/26/20, $39,032 , $9,368 , $48,400
Mikuls, Ted Richard, Investigations in Gout, Hyperuricemia, and Comorbidities(INSIGHT) Center of Research Translation (CORT), 20636, University of Alabama – Birmingham, 09/20/17-08/31/18, $32,698, $16,840 , $49,538
Summer Undergraduate Alcohol Research Program, 19990, DHHS/NIH/NIAAA, 04/01/18-03/31/22, $53,535, $2,468, $56,003
Driving Performance and Safety in Rheumatoid Arthritis, 21335, Rheumatology Research Foundation, 07/01/18-06/30/19, $185,185, $14,815, $200,000
O'Dell, James Robert, Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat (STOP GOUT), 22174, University of Nebraska Foundation, 12/01/17-11/30/22, $56,285, $0, $56,285